Folate, folic acid, and folinic acid (Leucovorin) in autism spectrum disorder: An evidence-based review
Year: 2025
Type: article
Abstract: ASD is a multifactorial neurodevelopmental disorder that is heterogeneous in nature. One-carbon metabolism that is dependent on foleate aids neurodevelopment in three ways: methylation, nucleotide synthesis and redox homeostasis. Alterations in folate conveyance and utilization, genetic, autoimmune, nutritional or iatrogenic, have been suggested as modifiable risk factors or symptom severity in sub-thoughts. This review is an attempt to synthesize mechanistic, epidemiologic, and clinical trial data on three related, but distinct, entities namely, (i) folate (the umbrella term describing tetrahydrofolate derivatives), (ii) folic acid (the fully oxidated synthetic vitamin which is used in fortification and supplements), and (iii) folinic acid (leucovorin, 5-formyl-THF), with particular attention to their potential role in ASD. We give an overview of evidence of maternal periconceptional supplementation and ASD risk, of autoantibodies of folate receptors-a (FRAA) and ASD phenotypes of cerebral folate deficiency (CFD) and folic acid, on folic acid used as a symptomatic therapy, biomarker-controlled selection (FRAA, CSF 5-MTHF, homocysteine), dosing and safety, and current controversies including unmetabolized folic acid (UMFA) and high dose exposure. There is evidence in favor of periconceptual folic acid-containing prenatal vitamins as primary prevention of neural tube defects and some evidence of a smaller effect of ASD risk in observational cohort studies. Small randomized controlled trials in the treatment show that high-dose folinic acid (usually 1-2 mg/kg/day, not exceeding 50 mg per day) can potentially be beneficial in terms of language and several core/associated symptoms in FRAA-positive children, although the sizes of the effects and the overall generalizability are questionable. Current professional advice does not encourage the use of leucovorin routinely by all children with ASD, unless there is clear demonstration (e.g. CFD/FRAA), until larger confirmatory studies are done. A practical, biomarker-driven clinical algorithm and research priorities conclude us.
Author: Abid Imtiyaz Mir
Language: English
Subfield: Nutrition and Dietetics
Field: Nursing
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4417310409
